Publication details large multicenter clinical trial demonstrating significant reductions in IBS symptoms through inFoods IBS guided dietary therapy IRVINE, Calif.,...
Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing...
WAYNE, Pa., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing...
BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field...
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage...
Event scheduled for Tuesday, December 2nd at 8:00 AM ETFort Lee, NJ, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma,...
NAARDEN, The Netherlands and MIAMI, Nov. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or...
Revolutionary PetVivo.ai Uses Nine AI Agents to Transform $150B Pet Care Market MINNEAPOLIS, Nov. 25, 2025 (GLOBE NEWSWIRE) -- PetVivo...
PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new...
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from...
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Anavex...
First patient recruited at leading Israeli site accelerating enrollment momentum across global study of CMND-100 Vancouver, Canada, Nov. 25, 2025...
NEW HAVEN, Conn., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that management will participate in...
Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027 KT-621 BREADTH Phase 2b...
WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to...
DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced...
CHAPEL HILL, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a...
SAN FRANCISCO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the...
First publicly listed company to actively investigate psilocybin’s potential impact on longevity NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) --...